KRAS and EGFR mutations coexisting in lung adenocarcinoma by Sousa, Vitor et al.
POSTER PRESENTATION Open Access
KRAS and EGFR mutations coexisting in lung
adenocarcinoma
Vitor Sousa
1,2,3,4*, Ana Alarcão
1,2, Patricia Couceiro
1,2, Maria R Silva
1,3, Maria J d’Aguiar
1, Lia Teixeira
1,
Lina Carvalho
1,2,3,4
From 16th International Charles Heidelberger Symposium on Cancer Research
Coimbra, Portugal. 26–28 September 2010
Lung adenocarcinoma represents about 42% and 28% of
NSCLC in women and men. Adenocarcinomas inci-
dence is still rising being the most frequent type of
NSCLC diagnosed in USA. Both EGFR and KRAS gene
mutations can contribute to the development of
NSCLC, namely adenocarcinomas. EGFR and KRAS
mutations are considered by some authors as mutually
exclusive explained by the fact that KRAS-MAPK path-
way is one of the downstream signalling pathways of
EGFR. Lung cancers with KRAS mutations are resistant
to EGFR tyrosine kinase inhibitors.
Sections of the adenocarcinoma of the lung, formalin-
fixed paraffin-embedded tissues (FFPE), were selected to
analyze mutations in EGFR exons 19 and 21 and
KRAS - codons 12 and 13 by DNA extraction for poly-
merase chain reaction (PCR). Exon 19 was studied by
fragment analysis and exon 21, codons 12 and 13 were
studied by direct sequencing. The analysis of FISH
results was done by Cappuzzo’ss c o r et oEGFR gene.
Determination of EGFR protein expression was done by
immunohistochemistry (IHC) (Zymed Laboratories).
The authors present a rare case with synchronous
EGFR and KRAS mutations. The patient is a 77 years
old, male with a central 3cm mixed adenocarcinoma.
The tumor showed EGFR protein overexpression identi-
fied by IHC and chromosome 7 high polyssomy by
FISH.
The authors call attention to the fact that although
EGFR and KRAS mutations are almost always mutually
exclusive in some cases they may coexist in the same
neoplasia.
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